Regenxbio, UPenn file patent suit against Sarepta related to new Duchenne gene therapy
Regenxbio, a Rockville, MD-based biotech, and the University of Pennsylvania sued Sarepta Therapeutics for the second time, this time alleging patent infringement for the company’s newly approved gene therapy for Duchenne muscular dystrophy.
The suit, filed last week in US District Court in the district of Delaware, alleges that Sarepta and Catalent, which manufactures Sarepta’s gene therapies, violated a patent for Elevidys, the brand name of Sarepta’s Duchenne treatment that received FDA approval last week.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.